Pharma stocks outlook: Four reasons why pharma stocks could fall out of favour as Covid recedes

0

As the regulatory work of USFDA gains pace, companies are likely to receive observations and alerts of the drug regulator.

Synopsis

The sector that had peaked out on the bourses in 2015 saw buying interest due to the focus on healthcare. However, the interest is likely to wane as Covid recedes.

ET Intelligence Group: One of the upticks of the Covid-ridden stock market was the revival of sentiment in pharma stocks. The sector that had peaked out on the bourses in 2015 saw buying interest due to the focus on healthcare. However, the interest is likely to wane as Covid recedes. 1. One-time boost from Covid drug salesThe brisk sale of Covid drugs provided an exceptional boost to the domestic sales of companies such as Cipla and Glenmark.

  • GIFT ARTICLE
  • FONT SIZE
  • SAVE
  • COMMENT

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Already a Member?

Why ?

  • Sharp Insight-rich, Indepth stories across 20+ sectors

  • Access the exclusive Economic Times stories, Editorial and Expert opinion

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

FOLLOW US ON GOOGLE NEWS

 

Source

Comments
Loading...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. AcceptRead More

Privacy & Cookies Policy